Eledon Pharmaceuticals Inc (ELDN) News

Eledon Pharmaceuticals to Present at the Cantor Global Healthcare Conference

IRVINE, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...

Eledon Announces Completion of Enrollment in Phase 2 BESTOW Clinical Trial Assessing Tegoprubart for Prevention of Organ Rejection in Kidney Transplant Patients

IRVINE, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]

Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]

Eledon Pharmaceuticals Reports Preliminary Second Quarter 2024 Operating Results

Presented updated data on 13 participants from ongoing Phase 1b trial evaluating tegoprubart for prevention of...

Form 8-K - Current report

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Eledon Provides Enrollment Update for Phase 2 BESTOW Trial Assessing Tegoprubart for the Prevention of Organ Rejection

IRVINE, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN...

Form 8-K - Current report

Form 8-K - Current report

Form 8-K - Current report

Eledon to Participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism

IRVINE, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities